(Q34776437)

4 August 2017

1 reference

title

Extrahepatic manifestations of cholestasis (English)

1 reference

4 August 2017

Helena Glasova

1

1 reference

PubMed ID

12167113

4 August 2017

Ulrich Beuers

series ordinal

2

1 reference

4 August 2017

1 September 2002

1 reference

Journal of Gastroenterology and Hepatology

4 August 2017

1 reference

4 August 2017

17

1 reference

4 August 2017

9

1 reference

4 August 2017

938-948

1 reference

Molecular pathogenesis of cholestasis.

4 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

21 January 2018

Hepatobiliary transport

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Understanding pruritus in systemic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Update on primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Quality of life before and after liver transplantation for cholestatic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Cholestatic liver diseases and health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Primary biliary cirrhosis in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

The pruritus of cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Pruritus--itching for a cause and relief?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Pruritic effect of bile salts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Pruritus in cholestasis: No direct causative role for bile acid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Raised histamine concentrations in chronic cholestatic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Serotonin receptor subtype antagonists in the medial ventral medulla inhibit mesencephalic opiate analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Effects of long-term rifampicin administration in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Rifampicin-induced elevation of serum bile acids in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Use of rifampin for severe pruritus in children with chronic cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Subhypnotic doses of propofol relieve pruritus associated with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Defining and measuring fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

The demography of primary biliary cirrhosis in Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Impact of fatigue on the quality of life of patients with primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Measuring the functional impact of fatigue: initial validation of the fatigue impact scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Augmented interleukin-1beta-induced depression of locomotor activity in cholestatic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Increased midbrain 5-HT1A receptor number and responsiveness in cholestatic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

5-HT1A receptor agonists: recent developments and controversial issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Opioid peptides and primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

21 January 2018

Hepatic osteodystrophy.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Low bone turnover state in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Osteoporosis and skeletal fractures in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Osteoporosis prevention, diagnosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Effect of vitamin K2 on osteoblast apoptosis: vitamin K2 inhibits apoptotic cell death of human osteoblasts induced by Fas, proteasome inhibitor, etoposide, and staurosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Risedronate: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

The effect of a single dose of osteoprotegerin in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02717.X

10.1046/J.1440-1746.2002.02717.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12167113